Multicenter Phase 1b/2 Study of Tivozanib in Patients with Advanced Inoperable Hepatocellular Carcinoma

The primary endpoint of the study is PFS at 24 weeks in patients with advanced HCC. Patients who remain alive without evidence of disease progression (per RECIST) for at least 24 weeks after enrollment will be considered PFS responders.

Study Number: 

I 229112

Early Phase
Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail